Sign in

CIK 0001563665

  • Non-accelerated filer
  • Smaller reporting company

Harvard Apparatus Regenerative Technology, Inc.

Sign in to watch
Ticker
HRGN
Exchange
OTC
Industry
Surgical & Medical Instruments & Apparatus
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
455210462
Phone
+1 774-233-7300
Business address
84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746
Former names
Biostage, Inc.
  1. 4 Open-market buy Chief Financial Officer bought 15,000 shares at $1.32 ($19,800)
  2. 4 Open-market buy Director bought 25,000 shares at $1.34 ($33,500)
  3. 4 Open-market buy Chief Medical Officer bought 9,500 shares at an average $1.29 ($12,210)
  4. 4 Other acquisition Chief Medical Officer acquired 10,284 shares (other)
  5. 4/A Open-market buy Chief Medical Officer bought 2,500 shares at $0.96 ($2,400)
  6. 4 Derivatives Options or other derivatives
  7. 4 Open-market buy Chief Medical Officer bought 2,500 shares at $0.96 ($2,400)
  8. 4 Open-market buy Chief Financial Officer bought 10,000 shares at $0.88 ($8,800)
  9. 4 Open-market buy Director bought 12,000 shares at $0.83 ($9,960)
  10. 4 Open-market buy Chief Financial Officer bought 100,000 shares at an average $0.66 ($65,500)
  11. 4 Open-market buy President and CEO bought 31,300 shares at an average $0.74 ($23,025)
  12. 3/A Insider 3/A
  13. 4 Open-market buy President and CEO bought 30,000 shares at an average $4.21 ($126,400)
  14. 4 Open-market buy Director bought 1,000 shares at $2.13 ($2,130)
  15. 4 Open-market buy Director bought 23,400 shares at $1.98 ($46,332)
  16. 4 Open-market buy Director bought 1,000 shares at $1.95 ($1,950)
  17. 4 Open-market buy Interim CEO & CFO bought 16,000 shares at an average $1.85 ($29,670)
  18. 4 Open-market buy Director bought 26,600 shares at $1.81 ($48,146)
  19. 4 Open-market buy Director bought 10,000 shares at $1.67 ($16,700)
  20. 4 Open-market buy Interim CEO & CFO bought 5,000 shares at $1.91 ($9,550)

Page 10 of 12 · 235 filings